GENFIT Announces EMA Support for Iqirvo® in PBC Treatment

Groundbreaking Milestone for GENFIT

GENFIT GNFT, a biopharmaceutical leader focusing on severe liver diseases, has just declared a significant stride forward in their pharmaceutical arsenal. On July 26, 2024, a pivotal opinion from the European Medicines Agency's (EMA) committee heralded a new era for patients battling Primary Biliary Cholangitis (PBC), thanks to GENFIT's licensed product, Iqirvo® (elafibranor).

Elafibranor: A Novel Therapy for PBC

After rigorous evaluation, the EMA committee has expressed a favorable opinion on elafibranor, marking a transformative point in PBC treatment options. With its specialized action on liver conditions, Iqirvo® is positioned to offer new hope for those impacted by this chronic disease, which often culminates in liver failure if left untreated.

Global Reach of GENFIT's Endeavors

Spanning multiple continents, GENFIT, headquartered in Loos, France, extends its influence through offices in Cambridge, Massachusetts and Zurich, Switzerland. This international footprint underscores the company's commitment to address rare liver disorders on a global stage. The synthesis of collaborative research across these hubs has been instrumental in pushing elafibranor closer to market accessibility, catering to a pressing medical need.

The Investment Trajectory of GNFT

As news of Iqirvo®'s acceptance by the EMA committee spread, GENFIT's presence in the stocks market, particularly represented by GNFT on Nasdaq and Euronext, is expected to undergo substantial scrutiny by investors. This development serves as a promising indicator of the company's potential for growth and its impetus in carving out a significant niche within the biopharmaceutical sector.

GENFIT, Iqirvo, EMA